Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corp    CVS

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

CVS Caremark 4th-Quarter Profit Rose 2.6% Amid Continued Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/06/2013 | 01:52pm CET
   By Tess Stynes 
 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as the company reported revenue growth in its pharmacy-services and retail drugstore operations.

For the year, the company raised its forecast for per-share adjusted earnings from continuing operations by two cents and now expects $3.86 to $4.

CVS's retail pharmacy business gained customers last year in the wake of a contract dispute between rival Walgreen Co.'s (>> Walgreen Company) and pharmacy-benefits manager Express Scripts Holding Co. (>> Express Scripts Holding Co) that has since been resolved.

A wave of major generic drugs introductions is having a mixed effect on the industry. Though the copycat drugs carry higher margins than branded products, they command lower prices, hurting sales revenue.

CVS Caremark reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-extinguishment losses, acquisition-related charges and other items, adjusted earnings from continuing operations were $1.14. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Revenue in the larger pharmacy-services business climbed 17% to $18.6 billion, reflecting new client starts, higher prices and growth of its Medicare Part D program. Pharmacy network claims processed rose 6.5%.

On the retail side, revenue increased 5.1% to $16.3 billion. Same-store sales were up 4% from a year earlier, as pharmacy same-store sales also improved by 4%. Same-store sales in the front end of the store grew 3.9%.

Shares closed Tuesday at $51.72 and were inactive premarket.

Write to Tess Stynes at tess.stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORP
01/14 CVS HEALTH : Canada Pension Plan Investment Board Has $249,866,000 Position in C..
01/14 CVS HEALTH : targets EpiPen with cheaper, generic version
01/13 CVS HEALTH : unveils generic competitor to EpiPen for one-sixth the price
01/13 CVS HEALTH : More Mylan misery
01/13 CVS HEALTH : Vende CVS versión genérica de Epipen a un sexto de su precio
01/12 CVS HEALTH : generic competitor to EpiPen, sold at a 6th the price
01/12 CVS HEALTH : puts out generic competitor to EpiPen at a 6th the price
01/12 CVS HEALTH : Flu Shots Available at CVS Pharmacy Locations in Washington
01/12 CVS HEALTH : Supporting Those Who Care for Our Aging Population
01/09 CVS HEALTH : Carjacking victim, shot nine times, suing CVS
More news
Sector news : Drug Retailers - NEC
01/11DJWalgreens to Offer FedEx Dropoff and Pickup at Walgreens Locations Nationwide
01/05 U.S. loses bid to overturn AmEx antitrust decision
01/05DJWALGREENS BOOTS CEO : No Plan B for Rite Aid Merger--Update
01/05DJWalgreens Boots Profit Slips--Update
01/05DJWalgreens Boots Raises Low End of Annual Guidance
More sector news : Drug Retailers - NEC
News from SeekingAlpha
01/13 BIOTECHS : What The 'Trump Dump' And CVS's EpiPen Move May Mean
01/12 Stocks Going Ex-Dividend The Third Week Of January
01/12 4 Dividend Growth Stocks The Trump Rally Left Behind
01/12 CVS Health to sell Impax Labs' generic epinephrine autoinjector for $109.99
01/12 Should I Buy Cisco Or CVS?
Advertisement
Financials ($)
Sales 2016 178 057 M
EBIT 2016 10 773 M
Net income 2016 5 672 M
Debt 2016 24 647 M
Yield 2016 2,00%
P/E ratio 2016 16,09
P/E ratio 2017 15,30
EV / Sales 2016 0,63x
EV / Sales 2017 0,60x
Capitalization 87 427 M
More Financials
Chart CVS HEALTH CORP
Duration : Period :
CVS Health Corp Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH CORP
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 88,0 $
Spread / Average Target 7,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Stephen J. Gold Chief Information Officer & Executive Vice Preside
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORP3.89%87 427
WALGREENS BOOTS ALLIAN..1.28%90 476
EXPRESS SCRIPTS HOLDIN..4.38%44 273
MCKESSON CORPORATION4.79%33 275
CARDINAL HEALTH INC4.21%24 005
AMERISOURCEBERGEN CORP..8.22%18 625
More Results